CANASA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Canasa, and when can generic versions of Canasa launch?
Canasa is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fourteen patent family members in thirteen countries.
The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Canasa
A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.
Summary for CANASA
International Patents: | 14 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 166 |
Clinical Trials: | 2 |
Patent Applications: | 4,477 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CANASA |
Drug Sales Revenues: | Drug sales revenues for CANASA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CANASA |
What excipients (inactive ingredients) are in CANASA? | CANASA excipients list |
DailyMed Link: | CANASA at DailyMed |



Recent Clinical Trials for CANASA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sandoz | Phase 3 |
Axcan Pharma | Phase 3 |
Forest Laboratories | Phase 3 |
Pharmacology for CANASA
Drug Class | Aminosalicylate |
Paragraph IV (Patent) Challenges for CANASA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CANASA | Suppository | mesalamine | 1000 mg | 021252 | 1 | 2013-05-24 |
US Patents and Regulatory Information for CANASA
CANASA is protected by two US patents.
Patents protecting CANASA
Mesalamine suppository
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Mesalamine suppository
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-002 | Nov 5, 2004 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-002 | Nov 5, 2004 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
Allergan | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-001 | Jan 5, 2001 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CANASA
See the table below for patents covering CANASA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 220397 | See Plans and Pricing | |
European Patent Office | 2512443 | SUPPOSITOIRE DE MÉSALAMINE (MESALAMINE SUPPOSITORY) | See Plans and Pricing |
European Patent Office | 2512443 | SUPPOSITOIRE DE MÉSALAMINE (MESALAMINE SUPPOSITORY) | See Plans and Pricing |
Mexico | 2012006902 | SUPOSITORIO DE MESALAMINA. (MESALAMINE SUPPOSITORY.) | See Plans and Pricing |
Chile | 2012001636 | Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa. | See Plans and Pricing |
Israel | 220397 | See Plans and Pricing | |
Japan | 2013514979 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |